| Previous Close | 1.6 |
| Open | 1.62 |
| Day High | 1.69 |
| Day Low | 1.57 |
| 52-Week High | 10 |
| 52-Week Low | 1.57 |
| Volume | 283,830 |
| Average Volume | 289,979 |
| Market Cap | 24.8M |
| PE | -0.5 |
| EPS | -3.28 |
| Moving Average 50 Days | 2.55 |
| Moving Average 200 Days | 3.51 |
| Change | 0.04 |
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
GlobeNewswire Inc.
Mar 04, 2026 12:30 PM GMT
Bioavailability data recently obtained from Phase 1 study with a stable crystal form of neflamapimod manufactured using a new, controlled manufacturing process Pharmacokinetic profile of the new, stable crystal form of neflamapimod largely overlaps w
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis
GlobeNewswire Inc.
Feb 18, 2026 11:00 AM GMT
Neflamapimod endorsement based on targeted mechanism of action, demonstrated clinical activity in neurodegenerative diseases, and encouraging translational data in ALS-relevant neurotoxicity models UK-based trial first to evaluate neflamapimod in ALS
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
GlobeNewswire Inc.
Dec 04, 2025 10:00 PM GMT
Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology Significant reduction in key neurodegeneration biomarker correlated with treatment response, suggestin